Clinical Trials

110 enrolled

Gynecologic

Endometrial Neoplasms

NCT04334941 2026-06-05

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

103 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

29 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05110781 2026-06-05

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

Phase 2 Terminated

1 enrolled 9 charts

DermatologicHead & Neck

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT05168618 2026-06-05

AtezoCab

33 enrolled

Prostatic Neoplasms

NCT05765084 2026-06-05

Immuno-MESODEC

GenitourinaryOther solid neoplasmThoracic

15 enrolled

Mesothelioma, Malignant, Wilms Tumor

NCT06161532 2026-06-05

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT06771518 2026-06-05

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

37 enrolled

Small Cell Lung Carcinoma

NCT03821246 2026-06-04

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

68 enrolled

Prostatic Neoplasms

NCT04160494 2026-06-04

D2C7-IT With Atezolizumab for Recurrent Gliomas

DermatologicGastrointestinalSarcomaThoracic

18 enrolled

CNS

Glioblastoma, Glioma

NCT06066138 2026-06-04

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase 1 Recruiting

30 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT06463665 2026-06-04

VIRO-25

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT07226999 2026-06-04

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Phase 2/3 Recruiting

550 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

550 enrolled

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT01810913 2026-06-03

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02997228 2026-06-03

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

120 enrolled

Colorectal Neoplasms

NCT03141684 2026-06-03

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

63 enrolled 1 FDA

Sarcoma

Sarcoma, Alveolar Soft Part

NCT04513925 2026-06-03

SKYSCRAPER-03

Phase 3 Completed

829 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04619797 2026-06-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

65 enrolled

Phase 2/3 Active not recruiting

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

430 enrolled

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05211323 2026-06-03

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

88 enrolled

Liver Neoplasms

NCT05703971 2026-06-03

Acclaim-3

62 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04303858 2026-06-02

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Phase 1 Terminated

189 enrolled

Other solid neoplasm

Solid Tumors

NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Phase 2/3 Recruiting

138 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04449874 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

498 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT04458922 2026-06-02

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

27 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT04487756 2026-06-02

VENEZO-LUNG

Phase 1/2 Completed

20 enrolled

Small Cell Lung Carcinoma

NCT04796012 2026-06-02

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

23 enrolled

Sarcoma

Rhabdomyosarcoma

NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

29 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06031441 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

250 enrolled

Other solid neoplasm

Locally Advanced Solid Tumors

NCT06492954 2026-06-02

AflacST2301

Phase 1 Recruiting

12 enrolled

Sarcoma

Osteosarcoma

NCT06632327 2026-06-02

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT07472517 2026-06-02

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

670 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

5,000 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02839707 2026-06-01

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

712 enrolled 14 charts

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT03811002 2026-06-01

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

544 enrolled 29 charts

Lung Neoplasms

NCT06096779 2026-06-01

Kirros

30 enrolled

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT06537310 2026-06-01

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

34 enrolled

Cancer-Neoplasms

NCT06646276 2026-06-01

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

530 enrolled

Small Cell Lung Carcinoma

NCT06712355 2026-06-01

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

621 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07195695 2026-06-01

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02693535 2026-05-29

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Terminated

190 enrolled 13 charts

Breast

Breast Neoplasms

NCT03228537 2026-05-29

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Other solid neoplasmThoracic

28 enrolled 17 charts

Mesothelioma, Malignant

NCT03289962 2026-05-29

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Completed

273 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

475 enrolled

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms

NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

24 enrolled